Key facts
- BrightInsight’s last known valuation is $750.0M (Mar 2021).
- It has raised $224.9M across 3 recorded rounds; the latest was Later Stage VC ($101.0M) in Mar 2021.
- Notable investors include General Catalyst, Insight Partners (New York), Gaingels, OurCrowd, Sand Hill Angels — 13 tracked in total.
- BrightInsight has filed 3 Form Ds with the SEC since 2019, most recently May 2021 ($101.0M sold to 22 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for BrightInsight
Funding rounds
3 roundsAbout BrightInsight
Developer of a digital health platform designed to optimize regulated drugs, devices, and software through integrated data and actionable insight. The company's platform uses software and services to capture, transmit, and analyze data from CE-marked and FDA-regulated medical devices, combination products, applications and software as a medical device, in compliance with security, privacy, and regulatory requirements, enabling biopharma and med-tech companies to accelerate their time to market, reduce the cost of implementation and scaling across products and global markets.
- Sector
- Healthcare
- HQ
- San Jose, CA, United States
- Founded
- 2017
- Employees
- 163
- Website
- brightinsight.com/
- Ownership
- Privately Held (backing)
BrightInsight doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BrightInsight shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BrightInsight in its N-PORT filings yet. We sweep new filings monthly.